Journal:

Article Title: Pituitary adenylate cyclase-activating polypeptide is an autocrine inhibitor of mitosis in cultured cortical precursor cells

doi:

Figure Lengend Snippet: Characterization of E13.5 cortical precursor cultures. Cells were incubated for 3 (a, b, d, e) or 24 h (c and f) and examined by phase (a and d) or brightfield microscopy to detect neuronal markers, immunoreactive MAP2 (b and c), and NSE (e and f). Neuronal markers increase from ≈50% at 3 h (b and e) to ≈90% at 24 h (c and f) (positive staining indicated by arrows; arrowhead = negative cells). Cells were unstained when primary antibody was omitted. MAP2 and NSE analyses were performed on five and two experiments, respectively. (Bar = 50 μm.)

Article Snippet: After 4% paraformaldehyde fixation (20 min), immunocytochemistry was performed with antibodies to MAP2 (1:1,000; I. Fischer, Medical College of Philadelphia), NSE (1:1,000; Polysciences), glial fibrillary acidic protein (1:1,000; Dako), RC1 (R. Schwarting, Dana–Farber Cancer Institute), myelin basic protein (1:500; D. Colman, Mt.

Techniques: Incubation, Microscopy, Staining

Journal: International Journal of Pharmaceutics: X

Article Title: Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery

doi: 10.1016/j.ijpx.2024.100283

Figure Lengend Snippet: Preparation variables and materials for LNPs.

Article Snippet: CV7202 , NCT03713086 , Phase 1 (2018–2021) , RABV-G mRNA using initial formulation CV7201 antigen with cationic protein protamine encapsulated in LNP , Ionizable amino lipid, DSPC, PEG-2000-DMG, Cholesterol , Rabies virus glycoprotein (RABV-G) , IM , ( ; ) , CureVac , Completed.

Techniques:

Journal: International Journal of Pharmaceutics: X

Article Title: Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery

doi: 10.1016/j.ijpx.2024.100283

Figure Lengend Snippet: Summary of ongoing or completed clinical trials utilizing LNPs. Formulation information is provided anywhere possible. Additional sources used in the construction of this table: https://clinicaltrials.gov ; https://classic.clinicaltrials.gov ; https://www.cdek.liu.edu . N/A: Formulation information not found, or any information identified were not peer-reviewed and not included.

Article Snippet: CV7202 , NCT03713086 , Phase 1 (2018–2021) , RABV-G mRNA using initial formulation CV7201 antigen with cationic protein protamine encapsulated in LNP , Ionizable amino lipid, DSPC, PEG-2000-DMG, Cholesterol , Rabies virus glycoprotein (RABV-G) , IM , ( ; ) , CureVac , Completed.

Techniques: Formulation, Virus, Membrane, Binding Assay, Recombinant, Vaccines, Modification, Infection, Expressing, Small Interfering RNA, CRISPR, Sequencing